vTv Therapeutics reports 2025 net loss of $27M; cash $88.9M; Phase 3 enrollment Q3 2026

vTv Therapeutics Inc.

Full-year 2025 net loss attributable to vTv of $27.0M ($3.20 basic EPS) vs $18.5M ($3.20 basic EPS) in 2024.
Cash and equivalents $88.9M at Dec 31, 2025, up from $36.7M; plus $20M non-dilutive from Newsoara in Feb 2026.
Expect to complete enrollment in Phase 3 CATT1 trial for cadisegliatin in T1D in Q3 2026.
R&D expenses rose to $17.9M in 2025 (2024: $11.5M) driven by higher cadisegliatin clinical spending.
Amended Newsoara license grants global rights to PDE4 inhibitor HPP737 for $20M upfront plus up to $115M milestones and royalties.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

vTv Therapeutics Inc. reported financial results for the full year ended December 31, 2025.

Period: the full year ended December 31, 2025
Result: reported results

Exact text from the filing

vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent corporate developments.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

vTv Therapeutics Inc. reported the fourth quarter ended December 31, 2025 results: net income $7.1 million, EPS $0.58 per basic share.

Period: the fourth quarter ended December 31, 2025
Net income: $7.1 million
EPS: $0.58 per basic share
Result: reported results

Exact text from the filing

Net loss attributable to vTv shareholders for the three months ended December 31, 2025, was $7.1 million or $0.58 per basic share.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-26-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.